The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients

Mazen T. Elkurd, Laxman B. Bahroo, Rajesh Pahwa

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia. When it is given at bedtime, it reaches plasma concentration approximately twice the level achieved by amantadine immediate release. Amantadine ER reduces the severity and duration of dyskinesia during the day, reduces OFF time and increases ON time without troublesome dyskinesia. The most common side effects are hallucination, dizziness, orthostatic hypotension and pedal edema. This review discusses the safety and efficacy of amantadine ER in dyskinesia in PD patients.

Original languageEnglish (US)
Pages (from-to)73-80
Number of pages8
JournalNeurodegenerative disease management
Volume8
Issue number2
DOIs
StatePublished - Apr 1 2018
Externally publishedYes

Keywords

  • ADS-5102
  • amantadine
  • amantadine ER
  • EASE
  • gutamate antagonist
  • levodopa-induced dyskinesia
  • NMDA antagonist
  • OFF time
  • Parkinson's disease
  • Unified Dyskinesia Rating Scale

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients'. Together they form a unique fingerprint.

Cite this